Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis
Diabetologia · 2024-11 · 67 (11) · 2507-2517
DOI: 10.1007/s00125-024-06246-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 06.08.2024. Verfasst von Lu You und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Lu.You@epi.usf.edu. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoantibodies, Phenotype. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIMS/HYPOTHESIS: Although statistical models for predicting type 1 diabetes risk have been developed, approaches that reveal the heterogeneity of the at-risk population by identifying clinically meaningful clusters are lacking. We aimed to identify and characterise clusters of islet autoantibody-positive individuals who share similar characteristics and type 1 diabetes risk. METHODS: We tested a novel outcome-guided clustering method in initially non-diabetic autoantibody-positive relatives of individuals with type 1 diabetes, using the TrialNet Pathway to Prevention study data (n=1123). The outcome of the analysis was the time to development of type 1 diabetes, and variables in the model included demographic characteristics, genetics, metabolic factors and islet autoantibodies. An independent dataset (the Diabetes Prevention Trial of Type 1 Diabetes Study) (n=706) was used for validation. RESULTS: The analysis revealed six clusters with varying type 1 diabetes risks, categorised into three groups based on the hierarchy of clusters. Group A comprised one cluster with high glucose levels (median for glucose mean AUC 9.48 mmol/l; IQR 9.16-10.02) and high risk (2-year diabetes-free survival probability 0.42; 95% CI 0.34, 0.51). Group B comprised one cluster with high IA-2A titres (median 287 DK units/ml; IQR 250-319) and elevated autoantibody titres (2-year diabetes-free survival probability 0.73; 95% CI 0.67, 0.80). Group C comprised four lower-risk clusters with lower autoantibody titres and glucose levels (with 2-year diabetes-free survival probability ranging from 0.84-0.99 in the four clusters). Within group C, the clusters exhibit variations in characteristics such as glucose levels, C-peptide levels and age. A decision rule for assigning individuals to clusters was developed. Use of the validation dataset confirmed that the clusters can identify individuals with similar characteristics. CONCLUSIONS/INTERPRETATION: Demographic, metabolic, immunological and genetic markers may be used to identify clusters of distinctive characteristics and different risks of progression to type 1 diabetes among autoantibody-positive individuals with a family history of type 1 diabetes. The results also revealed the heterogeneity in the population and complex interactions between variables.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Lu.You@epi.usf.edu.
- Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
- Faculty of Medicine, Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.
- Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Förderung
- NIDDK NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- JDRF
Zitieren
APA
You, L., Ferrat, L. A., Oram, R. A., Parikh, H. M., Steck, A. K., Krischer, J., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group (2024). Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis. Diabetologia, 67(11), 2507-2517. https://doi.org/10.1007/s00125-024-06246-w
Vancouver
You L, Ferrat LA, Oram RA, Parikh HM, Steck AK, Krischer J, et al. Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis. Diabetologia. 2024;67(11):2507-2517. doi:10.1007/s00125-024-06246-w
BibTeX
@article{You2024,
author = {You, Lu and Ferrat, Lauric A and Oram, Richard A and Parikh, Hemang M and Steck, Andrea K and Krischer, Jeffrey and Redondo, Maria J and Type 1 Diabetes TrialNet Study Group, Type 1 Diabetes TrialNet Study Group},
title = {Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {11},
pages = {2507--2517},
doi = {10.1007/s00125-024-06246-w}
}
EUVIMED